Singh et al. conducted a retrospective analysis of 5,936 hospitalizations in patients with type 2 diabetes who continued SGLT2 inhibitors during hospitalization and 30,569 who had them discontinued. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.